José Baselga
Hebron University(PS)Universitat Autònoma de Barcelona(ES)Memorial Sloan Kettering Cancer Center(US)National Cancer Centre Japan(JP)Massachusetts General Hospital(US)Vall d'Hebron Institut de Recerca(ES)Vall d'Hebron Hospital Universitari(ES)Vall d'Hebron Institute of Oncology(ES)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, PI3K/AKT/mTOR signaling in cancer, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck(2006)5,079 cited
- → Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer(2005)5,074 cited
- → Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis(2014)4,584 cited
- → Tumor mutational load predicts survival after immunotherapy across multiple cancer types(2019)4,299 cited
- → Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients(2017)3,455 cited
- → Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer(2011)2,803 cited